Overview
ConvEyXO develops miRNA-enhanced exosome therapeutics to address degenerative diseases at their biological roots and extend healthspan. The company uses stem cell-derived exosomes as cell-free therapies to target inflammation and cellular aging across multiple disease pathways.
Key people
In the news
- If you’re not already looking at exosomes, you’re probably late.” That was one of the most memorable messages we heard from a global pharma at BIO San Diego last week. The first exosome therapies are now in Phase 3, while a second generation of engineered exosome platforms is rapidly advancing into the clinic. Combined with major progress in manufacturing, characterization, and vesicle engineering, the conversation is shifting from potential to execution. At convEyXO, we’re excited to be part of this next generation helping
- What happens when the people who successfully predicted the future start betting on one thing? First the internet. Then smartphones. Then AI. Now, many of the world's most successful entrepreneurs and investors are turning their attention to longevity biotech. As legendary Silicon Valley investor Tim Draper recently said: "Aging is the one risk factor that affects 100% of the population. Every human is a potential customer. The largest addressable market that has ever existed." As Dasha Shunina put it its excellent article (link in
Related profiles
Something wrong or missing? Send an update. Fixed within 24 hours.